SG11201805123XA - Pharmaceutical composition comprising anti-human tslp receptor antibody - Google Patents
Pharmaceutical composition comprising anti-human tslp receptor antibodyInfo
- Publication number
- SG11201805123XA SG11201805123XA SG11201805123XA SG11201805123XA SG11201805123XA SG 11201805123X A SG11201805123X A SG 11201805123XA SG 11201805123X A SG11201805123X A SG 11201805123XA SG 11201805123X A SG11201805123X A SG 11201805123XA SG 11201805123X A SG11201805123X A SG 11201805123XA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical composition
- receptor antibody
- human tslp
- tslp receptor
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015246826 | 2015-12-18 | ||
| PCT/JP2016/087480 WO2017104778A1 (ja) | 2015-12-18 | 2016-12-16 | 抗ヒトｔｓｌｐ受容体抗体含有医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805123XA true SG11201805123XA (en) | 2018-07-30 |
Family
ID=59056678
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805123XA SG11201805123XA (en) | 2015-12-18 | 2016-12-16 | Pharmaceutical composition comprising anti-human tslp receptor antibody |
| SG10202012778YA SG10202012778YA (en) | 2015-12-18 | 2016-12-16 | Pharmaceutical composition comprising anti-human tslp receptor antibody |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202012778YA SG10202012778YA (en) | 2015-12-18 | 2016-12-16 | Pharmaceutical composition comprising anti-human tslp receptor antibody |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10994011B2 (zh) |
| EP (1) | EP3391904A4 (zh) |
| JP (3) | JP6897570B2 (zh) |
| KR (1) | KR20180088906A (zh) |
| CN (1) | CN108430507B (zh) |
| CA (1) | CA3008779A1 (zh) |
| HK (1) | HK1255877A1 (zh) |
| MX (1) | MX2018007520A (zh) |
| PH (1) | PH12018501243A1 (zh) |
| SG (2) | SG11201805123XA (zh) |
| TW (1) | TWI787161B (zh) |
| WO (1) | WO2017104778A1 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7374544B2 (ja) * | 2018-10-10 | 2023-11-07 | アステラス製薬株式会社 | 標識部－抗ヒト抗体Ｆａｂフラグメント複合体を含む医薬組成物 |
| UY39083A (es) * | 2020-02-13 | 2021-08-31 | Amgen Inc | Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria |
| CA3208743A1 (en) * | 2021-03-03 | 2022-09-09 | Lingjie Kong | Pharmaceutical composition containing anti-tslp antibody |
| CN116251181B (zh) * | 2021-12-02 | 2023-09-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp单克隆抗体的注射制剂 |
| WO2024098180A1 (en) * | 2022-11-07 | 2024-05-16 | Wuxi Biologics (Hong Kong) Limited | Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0852951A1 (de) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| MXPA02012747A (es) | 2000-06-28 | 2003-09-25 | Amgen Inc | Moleculas del receptor de linfopoietina estromica timica y sus usos. |
| SI1946776T1 (sl) | 2002-02-27 | 2017-07-31 | Immunex Corporation | Stabiliziran tnfr-fc sestavek, ki obsega arginin |
| SI2335725T1 (sl) | 2003-04-04 | 2017-01-31 | Genentech, Inc. | Visokokoncentrirane formulacije protiteles in proteinov |
| JP2007522157A (ja) | 2004-02-12 | 2007-08-09 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 抗ｅｇｆｒ抗体の高濃縮液体製剤 |
| US20050249712A1 (en) | 2004-03-23 | 2005-11-10 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Methods for use of TSLP and agonists and antagonists thereof |
| PE20081186A1 (es) | 2006-01-13 | 2008-09-24 | Irm Llc | Metodos y composiciones para el tratamiento de enfermedades alergicas |
| US7763070B2 (en) | 2006-07-25 | 2010-07-27 | C&C Vision International Limited | “W” accommodating intraocular lens |
| EP2170957A1 (en) | 2007-06-20 | 2010-04-07 | Irm, Llc | Methods and compositions for treating allergic diseases |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| CN101986784A (zh) | 2008-02-07 | 2011-03-16 | 先灵公司 | 基因工程tslpr抗体 |
| SG10201703707YA (en) | 2009-03-19 | 2017-06-29 | Chugai Pharmaceutical Co Ltd | Pharmaceutical formulation containing improved antibody molecules |
| TW201201840A (en) | 2010-07-15 | 2012-01-16 | Hoffmann La Roche | Antibodies specifically binding to human TSLPR and methods of use |
| US20120020960A1 (en) | 2010-07-26 | 2012-01-26 | Baylor Research Institute | Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer |
| AU2012250924B2 (en) | 2011-05-02 | 2017-05-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| WO2014031718A1 (en) | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| US9023357B2 (en) | 2013-03-15 | 2015-05-05 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| AR097293A1 (es) * | 2013-08-09 | 2016-03-02 | Astellas Pharma Inc | Anticuerpo contra el receptor de tslp humana |
-
2016
- 2016-12-16 TW TW105141843A patent/TWI787161B/zh active
- 2016-12-16 CA CA3008779A patent/CA3008779A1/en active Pending
- 2016-12-16 CN CN201680074501.1A patent/CN108430507B/zh active Active
- 2016-12-16 US US16/063,124 patent/US10994011B2/en active Active
- 2016-12-16 WO PCT/JP2016/087480 patent/WO2017104778A1/ja active Application Filing
- 2016-12-16 SG SG11201805123XA patent/SG11201805123XA/en unknown
- 2016-12-16 JP JP2017556456A patent/JP6897570B2/ja active Active
- 2016-12-16 SG SG10202012778YA patent/SG10202012778YA/en unknown
- 2016-12-16 KR KR1020187019908A patent/KR20180088906A/ko not_active Application Discontinuation
- 2016-12-16 EP EP16875754.0A patent/EP3391904A4/en active Pending
- 2016-12-16 MX MX2018007520A patent/MX2018007520A/es unknown
-
2018
- 2018-06-11 PH PH12018501243A patent/PH12018501243A1/en unknown
- 2018-11-22 HK HK18114960.7A patent/HK1255877A1/zh unknown
-
2021
- 2021-02-10 US US17/172,490 patent/US11712472B2/en active Active
- 2021-06-09 JP JP2021096266A patent/JP7208302B2/ja active Active
-
2023
- 2023-01-05 JP JP2023000355A patent/JP2023029500A/ja active Pending
- 2023-06-08 US US18/331,422 patent/US20230398213A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017104778A1 (ja) | 2017-06-22 |
| US20190111129A1 (en) | 2019-04-18 |
| JP2021127348A (ja) | 2021-09-02 |
| SG10202012778YA (en) | 2021-01-28 |
| CA3008779A1 (en) | 2017-06-22 |
| US20220023422A1 (en) | 2022-01-27 |
| TW202310873A (zh) | 2023-03-16 |
| TW201733618A (zh) | 2017-10-01 |
| HK1255877A1 (zh) | 2019-08-30 |
| JPWO2017104778A1 (ja) | 2018-10-04 |
| RU2018126355A (ru) | 2020-01-22 |
| JP6897570B2 (ja) | 2021-06-30 |
| JP7208302B2 (ja) | 2023-01-18 |
| KR20180088906A (ko) | 2018-08-07 |
| US20230398213A1 (en) | 2023-12-14 |
| PH12018501243A1 (en) | 2019-01-28 |
| TWI787161B (zh) | 2022-12-21 |
| US11712472B2 (en) | 2023-08-01 |
| MX2018007520A (es) | 2018-08-01 |
| JP2023029500A (ja) | 2023-03-03 |
| EP3391904A1 (en) | 2018-10-24 |
| RU2018126355A3 (zh) | 2020-03-10 |
| US10994011B2 (en) | 2021-05-04 |
| CN108430507A (zh) | 2018-08-21 |
| EP3391904A4 (en) | 2019-09-25 |
| CN108430507B (zh) | 2022-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501931A1 (en) | Anti-pdl1 antibody formulations | |
| SG11201805123XA (en) | Pharmaceutical composition comprising anti-human tslp receptor antibody | |
| PH12016501122A1 (en) | Delayed release compositions of linaclotide | |
| MY185802A (en) | Antibody formulation | |
| EP3206706A4 (en) | Stable injectable composition of pharmaceutically active agents and process for its preparation | |
| PH12015502041B1 (en) | Heteroaryl compounds and uses thereof | |
| TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
| MX2018015272A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
| MX2018015268A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
| MX2019004690A (es) | Constructos de anticuerpos. | |
| BR112017004393A2 (pt) | formulações de anticorpo | |
| MX2018015274A (es) | Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco. | |
| MX2017000527A (es) | Formulaciones de anticuerpos cristalinos. | |
| CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
| MX2021006003A (es) | Formulaciones de anticuerpos cristalinos. | |
| ZA201908610B (en) | Il-15 protein complex pharmaceutical composition and uses thereof | |
| TW201613557A (en) | Stable aqueous recombinant protein formulations | |
| AU2015316010A8 (en) | Crystalline forms of 6-( (6, 7-dimethoxyquinazolin-4-yl) oxy) -N,2-dimethylbenzofuran-3-carboxamide | |
| EP3204424A4 (en) | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies | |
| MX2016017142A (es) | Dispersion solida de allisartan isoproxilo y composicion farmaceutica que comprende la misma. | |
| MX2020002793A (es) | Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados. | |
| MX2017008983A (es) | Composición farmaceútica de sulfonamida. | |
| EP3612171A4 (en) | GEMCABED, PHARMACEUTICAL SALT THEREOF, COMPOSITIONS THEREOF, AND METHOD OF USE THEREOF | |
| MX2016004573A (es) | Inhibidores de nsp4 y metodos de uso. | |
| 陈琴 | An Ecofeminist Interpretation of the Country of the Pointed Firs |